Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESENTATION - AzurRx BioPharma, Inc. | presentation.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report
(Date of Earliest Event Reported): April 27, 2017
AzurRx BioPharma, Inc.
(Exact name of
registrant as specified in its charter)
Delaware
State or other
jurisdiction of incorporation
|
001-37853
|
46-4993860
|
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
760
Parkside Avenue
Downstate
Biotechnology Incubator, Suite 304
Brooklyn, New York 11226
(Address of
principal executive offices and zip code)
(646) 699-7855
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure
On April 27, 2017,
AzurRx BioPharma, Inc. (the "Company") began using the
corporate presentation materials attached hereto as Exhibit 99.1,
which presentation is posted on the Company’s website located
at www.azurrx.com. The Company may continue to use these materials
from time to time in conversations with investors and
analysts.
Item
9.01 Financial Statements and Exhibits
See Exhibit
Index.
Disclaimer
In accordance with
General Instruction B.2 of Form 8-K, the information contained in
Item 7.01 of this Current Report on Form 8-K, including Exhibit
99.1 attached hereto, shall not be deemed "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section. The
information in Item 7.01 of this Current Report on Form 8-K shall
not be incorporated by reference into any filing or other document
pursuant to the Securities Act of 1933, as amended, except as shall
be expressly set forth by specific reference in such filing or
document.
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Corporate Presentation
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
AZURRX BIOPHARMA,
INC.
By: /s/ Johan M. (Thijs)
Spoor
Name:
Johan M. (Thijs) Spoor
Title:
President and CEO
|
Dated: May 2,
2017